Kura Oncology, Inc. (KURA)

Kura Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-173.98	-152.63	-135.84	-130.47	-89.63
Depreciation & Amortization	0.85	0.85	0.76	0.56	0.19
Loss (Gain) From Sale of Investments	-13.14	-9.42	1.61	4.39	0.41
Stock-Based Compensation	33.9	28.08	26.32	23.58	12.81
Other Operating Activities	0.52	0.48	0.07	0.61	-
Change in Accounts Payable	15.2	10.33	-0.8	-2.52	5.68
Change in Unearned Revenue	278.18	-	-	-	-
Change in Other Net Operating Assets	-7.21	-2.51	-2.18	-0.71	0.71
Operating Cash Flow	134.32	-124.82	-110.06	-104.55	-69.83
Capital Expenditures	-0.47	-0.17	-0.63	-1.15	-2.17
Investment in Securities	-101.12	15.73	33.25	-125.69	-97.77
Investing Cash Flow	-101.59	15.56	32.63	-126.84	-99.94
Long-Term Debt Issued	-	-	10	-	-
Total Debt Issued	-	-	10	-	-
Long-Term Debt Repaid	-	-	-	-7.25	-0.25
Net Debt Issued (Repaid)	-	-	10	-7.25	-0.25
Issuance of Common Stock	154.42	94.78	29.14	4.43	469.58
Other Financing Activities	-	-	-0.58	-0.61	-
Financing Cash Flow	154.42	94.78	38.57	-3.44	469.33
Net Cash Flow	187.14	-14.48	-38.87	-234.82	299.57
Free Cash Flow	133.85	-124.99	-110.69	-105.7	-72
Free Cash Flow Margin	248.40%	-	-	-	-
Free Cash Flow Per Share	1.55	-1.71	-1.65	-1.59	-1.36
Cash Interest Paid	1.1	1.06	0.07	0.78	0.42
Levered Free Cash Flow	-55.93	-63.9	-63.67	-60.41	-42.36
Unlevered Free Cash Flow	-54.92	-62.93	-63.53	-60.15	-41.99
Change in Net Working Capital	-31.56	-11.94	2.57	1.1	-4.61

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q